Innovative Healthcare Institute shared on LinkedIn:
“Choosing a first-line approach for EGFR-mutated lung cancer can prompt a real debate.
Rafiullah Khan and Philip Leming will moderate Targeted Therapy 1 at Best of Lung Cancer 2026.
This session includes a debate on first-line treatment for sensitizing EGFR mutations, followed by discussion of rare EGFR mutations, ERBB2/HER2, NTRK, and RET.
Be part of the conversation on October 3 in West Chester, Ohio. Registration is free for healthcare professionals.”
You may also find this interesting:
Deulorlatinib in ALK-Positive NSCLC: Can Deuteration Improve on Lorlatinib?
